alk-in-5

ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK) with an IC50 of 2.9 nM.

ALK ROS1-IN-5 (compound X4) is a selective inhibitor of ALK and ROS1 kinases, with IC50 values of 0.512 μM for ALK and 0.766 μM for ROS1. It inhibits H2228 cells with an IC50 of 0.034 μM and induces apoptosis in cancer cells in a dose-dependent manner. Additionally, ALK ROS1-IN-5 effectively suppresses the expression of p-ALK and p-ERK in cancer cells.

ALK-5-IN-1, an ALK-5 inhibitor, can be utilized for cancer research and studying conditions involving fibrosis [1].

TGFβRI-IN-2 is a selective, potent and orally active inhibitor of (Activin-Like Kinase 5) ALK 5(pIC50 and pEC50 values of 7.6 and 6.63, respectively).

Trk-IN-7 (compound I-6) is a highly potent TRK inhibitor, with IC50 values of 0.25-10 nM for TRKA, TRKB, and TRKC, respectively. It also shows significant inhibition of EML4-ALK (IC50 <15 nM) and ALK mutations G1202R, C1156Y, R1275Q, F1174L, L1197M, and G1269A (IC50 = 5-50 nM) [1].

ALK5-IN-33 (Compound EX-10) is an orally active and selective inhibitor of ALK-5 with an IC50 ≤ 10 nM.

ALK5-IN-28 is a selective inhibitor of ALK-5 with an IC50 ≤ 10 nM that inhibits TGF-β-induced SMAD signalling.ALK5-IN-28 has the potential to inhibit tumour growth in vivo.ALK5-IN-28 can be used to study proliferative diseases (e.g. cancer, fibrotic diseases, systemic sclerosis).

ALK5-IN-25 (compound EX-02) is a potent ALK-5 inhibitor (IC50<10 nM) that also inhibits ALK-2 and can be used in cancer research.

ALK5-IN-31 is a selective inhibitor of ALK-5 (IC50≤10 nM) and also inhibits TGF-β-induced SMAD signalling.ALK5-IN-31 has the potential to inhibit tumour growth in vivo.ALK5-IN-31 can be used in the study of proliferative diseases (e.g. cancer, fibrotic diseases, systemic sclerosis).

ALK5-IN-32 is a selective inhibitor of ALK-5 (10 nMinhibits TGF-β-induced SMAD signaling.ALK5-IN-31 has the potential to inhibit tumor growth in vivo.ALK5-IN-31 can be used in the study of proliferative diseases (e.g. cancer, fibrotic diseases, systemic sclerosis). .

ALK5-IN-27 (Compound EX-04) is a potent inhibitor of ALK-5 (IC50 ≤ 10 nM) and also inhibits ALK-2.

CEP-14513 is a potent ALK inhibitor. CEP-14513 displayed potent ALK inhibitory activity in both in vitro enzymatic assay (IC50 = 5 nM) and cell-based assays of ALK tyrosine phosphorylation (IC50 = 30 nM).

XMU-MP-5 acts as a selective inhibitor of ALK. It inhibits ALK-mutant Ba F3 cells with an IC50 ranging from 4-50 nM and induces apoptosis in EML4-ALK Ba F3 cells. Additionally, XMU-MP-5 demonstrates antitumor activity in mice.